ETF in Focus: GREK
Health Care: Drugs
United Therapeutics Corporation (UTHR: NASDAQ)
$49.25 -0.16 | -0.32%
02/10/12 - 11:39 AM ET
153.81K / 1.01M
Vol / Avg. Vol:49.12 / 49.41
Open / Prev. Close:48.98 - 49.59
Today's Range:36.55 - 70.74
52 Wk Range:5.61%
Performance YTD:TheStreet Rating:
Portfolios with UTHR
- Portfolio NameUser Type
- Contributor8 Health Care Stocks Inside...
- ContributorStocks With Big Insider Buy...
- Contributor5 Biotech Stocks for 2012
- Contributor5 Low PEG / Low Beta Stocks
- Contributor13 Biotech Stocks Bought an...
- Contributor8 Health Care Stocks to Buy
- ProSAC Capital
- ContributorTheStreet Ratings Top-Rated...
- UserPART 6 JPMorgan 28th Annual...
- ContributorHealth Stock Short Squeezes
Latest UTHR Headlines from TheStreet
- United Therapeutics Gets Upgrade on Revenue Growth 01.12.12 | 08:01 am
- United Therapeutics Corporation Stock Upgraded (UTHR) 01.12.12 | 05:01 am
- 8 Health Care Stocks Insiders Are Bullish on 12.28.11 | 04:12 pm
- 5 Stocks Insiders Love Right Now 12.15.11 | 12:12 pm
- 5 Biotech Stocks for 2012 12.09.11 | 09:12 am
- 5 Low-Risk Stocks to Buy for 2012 12.01.11 | 06:12 am
- United Therapeutics Corporation (UTHR): Today's Featured Health Care Loser 11.10.11 | 04:11 pm
- United Therapeutics Corporation (UTHR): Today's Featured Drugs Loser 11.01.11 | 05:11 pm
- United Therapeutics' CEO Discusses Q3 2011 Results - Earnings Call Transcript 10.27.11 | 02:10 pm
- 8 Health Care Stocks to Buy 10.13.11 | 11:10 am
Press Releases for UTHR
- United Therapeutics Corporation To Announce Fourth Quarter And Annual 2011 Financial Results Before Market Open On Tuesday, February 14, 2012 - PR Newswire 02.07.12 | 07:02 am
- United Therapeutics Receives Paragraph IV Notice Letter For Remodulin - PR Newswire 02.06.12 | 07:02 am
- Intravenous Remodulin Approved For The Treatment Of Pulmonary Arterial Hypertension In Most Of The European Union - PR Newswire 12.27.11 | 07:12 am
- United Therapeutics Corporation To Announce Third Quarter 2011 Financial Results Before Market Open On Thursday, October 27, 2011 - PR Newswire 10.20.11 | 07:10 am
- United Therapeutics Prices Private Offering Of Convertible Senior Notes And Announces Concurrent Exercise Of Overallotment Option - PR Newswire 10.12.11 | 07:10 am
- United Therapeutics Announces Proposed Private Offering Of $210 Million Of Convertible Senior Notes And Authorization Of Stock Repurchase Program - PR Newswire 10.11.11 | 07:10 am
- United Therapeutics Subsidiary Enters Into Contract With National Institutes Of Health For Award Of Up To $45 Million To Support Glycobiology Antiviral Program - PR Newswire 10.10.11 | 07:10 am
- FREEDOM-C(2) Trial Of Oral Treprostinil In Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint - PR Newswire 08.24.11 | 05:08 am
- United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open On Thursday, July 28, 2011 - PR Newswire 07.21.11 | 07:07 am
- FREEDOM-M Trial Of Oral Treprostinil In Pulmonary Arterial Hypertension Meets Primary Endpoint - PR Newswire 06.06.11 | 05:06 am
Partner Headlines for UTHR
- A Baker's Dozen Of Top Value-Stocks For 2012: Part III - Seeking Alpha 02.03.12 | 08:02 am
- Activist Hedge Fund Accipiter Capital's Top Stock Picks - Seeking Alpha 11.29.11 | 09:11 am
- Zacks Releases Four Powerful ''Buy'' Stocks: United Therapeutics, Monsanto, Universal and Genesco - Press Releases - Zacks 11.29.11 | 09:11 am
- United Therapeutics Corp - Aggressive Growth - Zacks 11.29.11 | 01:11 am
- United Therapeutics (UTHR) - Bull of the Day - Zacks 11.11.11 | 01:11 am
- Calls Purchased on United Therapeutics - Benzinga 07.08.11 | 01:07 pm
- Pluristem Therapeutics Pops on Licensing Pact - Benzinga 06.20.11 | 04:06 pm
- UPDATE 2-Ex-Nasdaq exec pleads guilty over insider trading - Reuters 05.26.11 | 05:05 pm
- Earnings Decline at UTHR - Analyst Blog - Zacks 05.04.11 | 06:05 pm
- Goldman Sachs Suggests Buying Calendar Spreads on United Therapeutics Corporation (UTHR) - Benzinga 03.09.11 | 09:03 am
